MOUNTAIN VIEW, Calif.,
Jan. 30, 2011 /PRNewswire/ -- MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it will
hold a conference call at 8:30 a.m. Eastern
Time tomorrow, Monday, January 31, to discuss partnering
plans for LEVADEX™. LEVADEX is MAP Pharmaceuticals' novel,
orally inhaled, migraine therapy that has completed Phase 3
clinical development for the treatment of acute migraine.
Conference Call / Webcast Details
To participate in the live call on Monday, January 31, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), please dial 877-280-7473
for domestic callers and 707-287-9370 for international callers.
Individuals interested in listening to the live call via webcast
may do so by visiting the Investor Relations page of
http://www.mappharma.com.
About MAP Pharmaceuticals
MAP Pharmaceuticals is an emerging biopharmaceutical company
focused on developing and commercializing new therapies to address
undermet patient needs in neurology. The Company is developing
LEVADEX™ orally inhaled therapy for the potential treatment of
migraine and has reported positive results from the efficacy
portion of its Phase 3 trial of LEVADEX. In addition, MAP
Pharmaceuticals generates new pipeline opportunities by applying
its proprietary drug particle and inhalation technologies to
enhance the therapeutic benefits of proven drugs, while minimizing
risk by capitalizing on their known safety, efficacy and
commercialization history.
Additional information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
|
CONTACTS:
|
|
|
Nicole Foderaro
|
|
|
WCG
|
|
|
(415) 215-5643
|
|
|
nfoderaro@wcgworld.com
|
|
|
SOURCE MAP Pharmaceuticals, Inc.